BIOTECH ASSISTANT / FIELD NOTES

Hovione commits $35 million to integrated U.S. continuous tableting

Company / institutional announcement · Hovione

Source published: 2026-10-05

Site published: 2026-11-03 · Updated: 2026-11-03

Explore this article with AI

This source is linked automatically. Choose a question to get started.

Ask AI ↗

Findings and limitations Industry implications Related developments

What changed

Hovione plans to install a $35 million ConsiGma CDC Flex line at its East Windsor, New Jersey, campus, with commissioning expected in late 2027. The system will link spray-dried amorphous solid dispersions to tablet production under one quality system. Planned continuous and batch modes span 1 to 200 kilograms per hour, with development possible using 1.5 kilograms.

Why it may matter

Integrating solubility enhancement with downstream tableting could reduce handoffs, while claims of avoiding traditional scale-up still require product-specific validation data.

The interpretation above is analysis, not a conclusion attributed to the original source.

Read the original source ↗

Prepared through Biotech Assistant’s automated research workflow. Editorial standards and corrections

Formulation Development & Manufacturing

Follow the evidence

Companies mentionedHovione ↗

Explore field companies →Explore literature →

Related updates

2026-11-05Nature Communications

Peptide–oligonucleotide nanohybrids deliver miRNA to injured bone in rats

A Nature Communications study reports a peptide–oligonucleotide nanohybrid for bone-targeted miR-26a-5p delivery. The original abstract describes reduced GSK-3β expression and stabilization of HIF-1α, supporting coupled bone formation and angiogenesis. Systemic administration limited skeletal and vascular injury in a rat glucocorticoid-induced bone-loss model. This is preclinical miRNA delivery, not oral cyclic peptide therapy or human efficacy evidence.

Oligonucleotide Therapeutics & Delivery Formulation Development & Manufacturing Ask AI ↗

2026-11-05U.S. Food and Drug Administration

FDA grants accelerated approval for subcutaneous amivantamab combination in selected head and neck cancers

FDA granted accelerated approval to amivantamab and hyaluronidase-lpuj for adults with recurrent or metastatic head and neck squamous cell carcinoma after platinum chemotherapy and an anti-PD-(L)1 antibody. HPV-associated oropharyngeal cancer is excluded. In the 102-patient OrigAMI-4 efficacy population, response rate was 42%. Continued approval requires confirmatory clinical benefit; this is not traditional full approval.

Formulation Development & Manufacturing Ask AI ↗

2026-11-05Phillips Medisize / Business Wire

Phillips Medisize acquires full Chippenham site footprint for inhalation development

Phillips Medisize announced an investment to acquire the complete footprint of its Chippenham site in England, strengthening its Global Inhalation Center of Excellence alongside Cambridge. Building on the 2025 Vectura acquisition, the site supports drug-device formulation development and early- and late-stage clinical supplies. The announcement links the investment to anticipated growth in complex inhaled therapies.

Formulation Development & Manufacturing Ask AI ↗

Continue your research

All company profiles, filters, and comparisons are open. Sign in for private saves and member discussions.

Open full company map ↗